21. Impact of three-dimensional vision in laparoscopic partial nephrectomy for renal tumors

22. {tRNA}-Derived Fragments ({tRFs}) in Bladder Cancer: Increased 5$\prime$-{tRF}-{LysCTT} Results in Disease Early Progression and Patients' Poor Treatment Outcome

23. Analytical methodologies for the detection of SARS-CoV-2 in wastewater: Protocols and future perspectives

24. miR -181a overexpression predicts the poor treatment response and early-progression of serous ovarian cancer patients

25. Blood-based analysis of 84 microRNAs identifies molecules deregulated in individuals with type-2 diabetes, risk factors for the disease or metabolic syndrome

26. Circulating miR-146a and miR-134 in predicting drug-resistant epilepsy in patients with focal impaired awareness seizures

27. Circulating exosomal miRNAs: clinical significance in human cancers

28. miR-203 is an independent molecular predictor of prognosis and treatment outcome in ovarian cancer: a multi-institutional study

29. HPV16 E6/E7 expression in circulating tumor cells in oropharyngeal squamous cell cancers: A pilot study

30. Revisiting Histone Deacetylases in Human Tumorigenesis: The Paradigm of Urothelial Bladder Cancer

31. Unraveling UCA1 lncRNA prognostic utility in urothelial bladder cancer

32. Gene-Specific Intron Retention Serves as Molecular Signature that Distinguishes Melanoma from Non-Melanoma Cancer Cells in Greek Patients

33. Blood-based analysis of type-2 diabetes mellitus susceptibility genes identifies specific transcript variants with deregulated expression and association with disease risk

34. The lysine-specific methyltransferase KMT 2C/ MLL 3 regulates DNA repair components in cancer

35. Molecular Effects of Treatment of Human Colorectal Cancer Cells with Natural and Classical Chemotherapeutic Drugs: Alterations in the Expression of Apoptosis-related BCL2 Family Members, Including BCL2L12

36. Loss of GAS5 tumour suppressor lncRNA: an independent molecular cancer biomarker for short-term relapse and progression in bladder cancer patients

37. miRNA and long non-coding RNA: molecular function and clinical value in breast and ovarian cancers

38. BCL2L12 improves risk stratification and prediction of BFM-chemotherapy response in childhood acute lymphoblastic leukemia

39. Clinical utility of miR-143/miR-182 levels in prognosis and risk stratification specificity of BFM-treated childhood acute lymphoblastic leukemia

40. miR-221/222 cluster expression improves clinical stratification of non-muscle invasive bladder cancer (TaT1) patients risk for short-term relapse and progression